Related Experiment Videos
Immunoadsorption in lupus myocarditis
Ioannis Griveas1, Aggelos Sourgounis, Georgios Visvardis
1Nephrology Department, Papageorgiou General Hospital, Thessaloniki, Greece. giannisgriv@hotmail.com
Summary
Immunoadsorption (IA) offers a promising rescue therapy for severe lupus myocarditis, a rare but life-threatening condition. This treatment, combined with immunosuppression, significantly improved a patient's cardiac function and overall health.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) can present with severe, life-threatening myocarditis, often driven by autoimmunity.
- Current therapeutic options for fulminant lupus myocarditis are limited, necessitating novel treatment strategies.
Observation:
- A 29-year-old male with SLE developed severe lupus myocarditis, presenting with cardiogenic shock and a critically low ejection fraction (20%) despite standard treatments.
- Conventional therapies including immunosuppressants and plasmapheresis failed to stabilize the patient's condition.
Findings:
- Immunoadsorption (IA) using staphylococcal protein A was administered as a rescue therapy.
- Following 6 IA sessions combined with immunosuppression, the patient showed significant clinical improvement, with ejection fraction increasing to 50%.
Implications:
- IA, in conjunction with immunosuppressive therapy, demonstrated significant benefit in a case of severe lupus myocarditis.
- This case suggests IA may be a valuable therapeutic option for fulminant lupus myocarditis, warranting further investigation in pilot studies.